The successful candidate will be part of a collaborative project consisting of chemists and molecular/structural biologists who aim to design catalytic inhibitors targeting the human deubiquitylates USP25 and USP28. Both DUBs are considered key targets for the development of pharmacological therapies against specific types of cancer as well as autoimmune and neurological diseases and several bi-specific inhibitors are know. The candidate will use various methods, including X-ray crystallography, cryo EM and different biophysical/biochemical methods, to guide the development of existing and novel inhibiting compounds towards high selectivity and potency.
For more information, please visit the website.
